2022-11-10FDA approves tremelimumab in combination with durvalumab and platinum-based chemotherapy for metastatic non-small cell lung cancerTrial POSEIDONDrugs Imjudo (tremelimumab) · Anti-CTLA-4 antibody, Imfinzi (durvalumab) · Anti-PD-L1 antibodyConditionThoracic
2020-10-02FDA approves nivolumab and ipilimumab for unresectable malignant pleural mesotheliomaTrial CheckMate743Drugs OPDIVO (nivolumab) · Anti-PD-1 antibody, YERVOY (ipilimumab) · Anti-CTLA-4 antibodyConditionsOther solid neoplasmThoracic
2020-05-26FDA approves nivolumab plus ipilimumab and chemotherapy for first-line treatment of metastatic NSCLCTrial CheckMate 9LADrugs OPDIVO (nivolumab) · Anti-PD-1 antibody, YERVOY (ipilimumab) · Anti-CTLA-4 antibodyConditionThoracic
2020-05-15FDA approves nivolumab plus ipilimumab for first-line mNSCLC (PD-L1 tumor expression ≥1%)Trial CheckMate 227Drugs OPDIVO (nivolumab) · Anti-PD-1 antibody, YERVOY (ipilimumab) · Anti-CTLA-4 antibodyConditionThoracic